Pharmx Technologies Limited · ASX:PHX
Pharmx Technologies — H1 FY24 Earnings Presentation
22 slides from Pharmx Technologies's earnings presentation, Feb 23, 2024
Slide 1: Investor Presentation
For personal use only PharmX Technologies Limited Investor Presentation CEO Tom Culver & Interim CFO Jon Newbery 23 February 2024 This presentation has been authorised for lodgment by the Board
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by PharmX Technologies Limited (PHX assurance that the results, performance or achievements expressed or For personal use only or the Company or PharmX). It should not be considered as an offer or implied by the forward-looking statem
Slide 3: Presenters
Presenters For personal use only Thomas Culver Jon Newberry Chief Executive Officer Non-Executive Director (interim CFO) • 20y experience in CEO and Snr Exec • 30y experience in Snr Exec and Board for Private and ASX listed Co. roles for ASX listed Co. • Previously Chief Operating Officer of • Chair
Slide 4: PharmX Technologies Overview
For personal use only PharmX Technologies Overview FY24 • Well capitalized and • 1H FY 24 streamlined focus positioned as a strong • Legacy Corum Group (+25ys on technology orientated platform for growth in operation) business: PHX, PHXC, MDS Focused and ambitious • Disposal of the eCommerce • • Foc
Slide 5: PharmX Technologies Limited
For personal use only PharmX Technologies Limited Critical EDI infrastructure to the industry supply chain of retail , Purpose-built marketplace for pharmacists and suppliers pharmaceutical and NDSS goods Est. Est. 2006 2022 Primary customer: Primary customer: Supplier Pharmacy / Supplier Service: S
Slide 6: Key Updates H1 FY24
Key Updates H1 FY24 For personal use only PharmX PharmXchange Master Data Services Staffing Continued focus on EDI Development support brought Rollout of phase 1 Data Thomas Culver appointed as solutions. Supporting Gateways in-house Solution –(industry product the new PharmX Technologies 2
Slide 7: Key Financial Updates H1 FY24
Key Financial Updates H1 FY24 For personal use only Operating results Capital Return Court Case Revenue growth of 5%, while The disposal of the pharmacy Judgement handed down in delivering a strong EBITDA software business was 2023 by the Victorian Supreme margin of 33%. completed in September
Slide 8: New Focused Team Structure
New Focused Team Structure Thomas Culver CEO For personal use only Finance/Operations Commercial/Sales Product/Technology Marketing/Brand Data Services Chief Financial Officer GM Commercial Enterprise Architect Head of Brand and Marketing Head of Data Senior Accountant Partnership Manager Head of P
Slide 9: PharmX EDI Developments
PharmX EDI Developments Gateway 4 Master Date Solutions For personal use only Service Gateway 4 Orders - Traditional EDI Invoices - (Gateway 1 – 3) Advanced Shipping Notices - Account Management - Enhanced EDI (Gateway 3) Supplier Inventory - Retail Sales - Master Data Platform PharmX and PharmXchan
Slide 10: PharmXchange Overview
For personal use only PharmXchange Overview +240 Brands 11k highly discoverable Multi item checkout, Near term focus with platform exclusive to increase activation products, with supplier sponsorship W/S stock / payments info promotions and engagement AI driven experience (trending, recommender syst
Slide 11: Profit and Loss H1 FY24
For personal use only Profit and Loss H1 FY24 Revenue growth of 5%, while delivering a strong EBITDA margin of 33% $’000 H1 FY24 H1 FY23 Var $ Var % Revenue 3,235 3,082 153 5% • Underlying results exclude the pharmacy software business and non-recurring costs Underlying costs (2,155) (2,362) 207 (9)
Slide 12: Loss from discontinued operations
For personal use only Loss from discontinued operations Loss from discontinued operations includes the loss on disposal and the results from operations until disposal $’000 H1 FY24 Proceeds on disposal 6,250 • The sale of the pharmacy software business to Jonas Net tangible asset deficiency to be pa
Slide 13: Cashflow for H1 FY24
For personal use only Cashflow for H1 FY24 Continuing Positive Operating Cashflow $'000 H1 FY24 H1 FY23 Var $ Var % Receipts from customers - continuing 3,298 3,243 55 2% operations Statutory Operating Cashflow 1,936 1,700 236 14% • Underlying operating cashflow was positive both Add-Back Non-recurr
Slide 14: Closing Summary
For personal use only Closing Summary A positive result for 1HFY24, with opportunities for growth • Independent service provider to the pharmacy market with focused business model and product solutions • Long term opportunities for product optimization and service expansion to increase market domina
Slide 15: Questions
For personal use only Questions
Slide 16: Thank You
For personal use only Thank You Contact: Investor.Relations@pharmx.com.au
Slide 17: Appendix
For personal use only Appendix
Slide 18: Corporate Overview
For personal use only Corporate Overview PharmX Technologies Limited (ASX:PHX) at Capital Structure 19 February 2024 Share Price 2.7cps Shares on Issue (m) 598.5 Market Capitalisation $16.2m Options / Perf Rights (m) 11.9 Enterprise Value (Cash 31/12/24) $3.8m Diluted Issued Capital (m) 610.4 On 22
Slide 19: Profit & Loss
For personal use only Profit & Loss Profit & Loss ($'000) H1'24 H1'23 ∆ PCP Revenue from continuing operations $3,235 $3,082 5% Cost of sales ($610) ($614) (1)% Employee benefits ($1,022) ($1,186) (14)% Marketing ($65) ($84) (23)% Technology, communication and cloud costs ($201) ($174) 16% Legal ($7
Slide 20: Cashflow
For personal use only Cashflow Cash flow ($'000) H1 FY24 H1 FY23 Cash flows from operating activities Receipts from customers 4,683 6,587 Payments to suppliers and employees (4,503) (6,474) Interest and other revenue received 93 37 Research and development incentive received, net of income tax paid
Slide 21: Balance Sheet
Balance Sheet 31 December 24 - H1 Balance Sheet ($'000) 30 June 23 - H2 FY23 FY24 For personal use only Current assets Cash and cash equivalents $12,440 $12,806 Trade and other receivables $2,652 $946 Income tax receivable $498 $1,659 Other assets $222 $229 Assets classified as held for sale - $6,94
Slide 22: Share Registry
For personal use only Share Registry Top shareholders at 19 February 2024 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 89,480,946 14.95% 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.02% 3 NATIONAL NOMINEES LIMITED 40,242,512 6.72% 4 MERSAULT PTY LTD<ENGLAND S/F A/C> 26,766,667 4.